Janet Woodcock, Paul Kim join Friends’ board of directors

Makary vows to speed up drug approvals and end FDA’s “cozy” relationship with industry
Commissioner promises to protect scientific integrity while bringing in “fresh” MAHA ideas

In his first sit-down interview since beginning his role as FDA commissioner 17 days earlier, Marty Makary, a former Johns Hopkins surgeon and the only Trump pick for HHS whose confirmation received Democratic support, said he would speed up approvals for rare-disease treatments by reducing reliance on animal testing and shifting towards organoids and computational models.

April 25, 2025

Vol.51 No.16

By Claire Marie Porter

Ci4CC’s 23rd Cancer Center Summit to focus on accelerating oncology innovation through AI

We are at a transformational period in oncology; the overall mortality from cancer is gradually declining in the United States.

April 25, 2025

Vol.51 No.16

By Suresh S. Ramalingam and Adam Marcus

Advancing peritoneal oncology: Innovations in surgical strategies and research

Peritoneal metastases arise from gastrointestinal and gynecologic malignancies, leading to debilitating symptoms and poor prognoses. They remain one of the most challenging manifestations of advanced malignancies, often leading to significant morbidity and limited treatment options.

ASCO seeks to engage new leaders of NIH, CMS, and FDA

The Association for Clinical Oncology has reached out to the new leaders of federal health agencies to ensure continued progress in cancer care, research, and patient access, the organization said.

NSF director Sethuraman Panchanathan to resign

Sethuraman Panchanathan, director of the National Science Foundation, will resign from the position 16 months before the scheduled end of his six-year term.

April 25, 2025

Vol.51 No.16

By Jacquelyn Cobb and Claire Marie Porter